Professional Documents
Culture Documents
Diltiazem
Diltiazem
ti ti(
Indication: Treatment of paroxysmal supraventricular tachycardia, atrial fibrillation, or atrial flutter.
LBS 90 100 110 120 130 140 150 160 170 180 190 200
KG 41 45 50 55 59 64 68 73 77 82 86 90
3. Maintenance IV Infusion
Begin IV infusion if HR >100 bpm and BP >90/60 mmHg 15 minutes after 0.35rng/kg IV bolus dose.
15 minutes after start of Discontinue infusion Continue infusion at 5mg/hr Increase infusion to 10mg/hr
Infusion at 5mg/hr
After 15 minutes of infusion Decrease infusion to 5mg/hr Continue infusion at 10mg/hr Increase infusion to 15mg/hr
at 10mg/hr
After 15 minutes of infusion Decrease infusion to 10mg/hr Continue infusion at 15mg/hr Call physician for additional
at 15mg/hr order
If HR is < 60 bpm or BP < 90/60 mmHg, stop infusion and contact physician.
Continuous IV therapy via infusion pump should be used no longer than 24 hours.
C. Monitoring
With patient on monitored bed status, monitor patient's BP and HR with initiation of drip and each infusion rate change as follows:
1.Every 5 minutes x3
2.Every 15 minutes x3
3. Every 30 minutes x2
4. Every 1 hour until drip is discontinued
D. Dilution
Mix as directed for continuous infusion at 10mg/hr. Mixture is compatible with D5W, dobutamine, dopamine, lidocaine, and
nitroglycerin. Mixture is incompatible when mixed directly with furosemide.
• Once heart rate is controlled, the infusion may be discontinued. Oral diltiazem should be started immediately after IV
discontinuation.
• Initiate with immediate release product at discontinuation of the infusion then start a long-acting product at the next
scheduled dose time.
References
2. GObel E, Hautvast R, Lie K, et al. Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate
for unstable angina pectoris. Lancet. December 23, 1995;346(8991-8992):1653-1657